NRx Pharmaceuticals, Inc. is a pharmaceutical company based in Wilmington, DE that focuses on developing breakthrough medicines for individuals suffering from life-threatening conditions such as bipolar depression, post-traumatic stress disorder (PTSD), chronic pain, and suicidal ideation. Their lead candidate, NRX-101, is the first oral medication currently undergoing FDA trials for suicidal bipolar depression, offering hope to those in need of effective treatment options.
With a strong emphasis on scientific research and clinical approach, NRx Pharmaceuticals aims to address the urgent need for non-addictive and non-sedating pain medication in light of the ongoing opioid crisis. Their commitment to innovation and development is evident through their collaborations with Lotus Pharmaceuticals and Alvogen Inc. to commercialize NRX-101, as well as their FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation for the treatment of complicated urinary tract infections and pyelonephritis.
Generated from the website